[1]
Inwood B. Ethics and human action in early stoicism. Oxford: Clarendon Press 1985.
[2]
Krack P, Pagonabarraga J, Strafella AP, Kulisevsky J. Apathy: Who cares? Lancet Neurol 2015; 14: 465.
[3]
Fisher CM. Honored guest presentation: Abulia minor vs. agitated behavior. Neurosurgery 1984; 31(Suppl. 1): 9-31.
[4]
Marin RS. Differential diagnosis and classification o apathy. Am J Psychiatry 1990; 147(1): 22-30.
[5]
Marin RS. Apathy. A neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3: 243-54.
[6]
Berrios GE, Gili M. Abulia and impulsiveness revisited: a conceptual history. Acta Psychiatr Scand 1995; 92: 161-7.
[7]
Stuss DT, Van Reekum R, Murphy KJ. In Borod JC, Eds. The
Neuropsychology of Emotion. Oxford: Oxford University Press
2000; pp. 340-63.
[8]
Laplane D, Dubois B. Auto-activation deficit: a basal ganglia related syndrome. Mov Disord 2001; 16(5): 810-4.
[9]
Habib M. Athymhormia and disorders of motivation in basal ganglia disease. The J Neuropsychiatry Clin Neurosci 2004; 16: 509-24.
[10]
Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 2006; 16: 916-28.
[11]
Starkstein SE, Leentjens AFG. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry 2008; 79: 1088-92.
[12]
Le Heron C, Apps MAJ, Husain M. The anatomy of apathy: A neurocognitive framework for amotivated behaviour. Neuropsychologia 2018; 118: 54-67.
[13]
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
[14]
Sockeel P, Dujardin K, Devos D, Denève C, Destée A, Defebvre L. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006; 77: 579-84.
[15]
Robert P, Onyike CU, Leentjens AFG, et al. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. J Eur Psychiatry 2009; 24: 98-104.
[16]
Starkstein SE. Apathy and withdrawal. Int Psychogeriatr 2000; 12(Suppl. 1): 135-8.
[17]
Mulin E, Leone E, Dujardin K, Delliaux M, et al. Diagnostic criteria for apathy in clinical practice. Int J Geriatr Psychiatry 2011; 26: 158-65.
[18]
Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998; 10: 314-9.
[19]
García-Ramos R, Villanueva C, del Val J, Matías-Guíu J. Apatía en la enfermedad de Parkinson. Neurologia 2010; 25(1): 40-50.
[20]
Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis 1994; 182: 235-9.
[21]
Hama S, Yamashita H, Shigenobu M, et al. Depression or apathy and functional recovery after stroke. Int J Geriatr Psychiatry 2007; 22: 1046-51.
[22]
Van Reekum R, Stuss DT, Ostrander L. Apathy: Why care? J Neuropsychiatry Clin Neurosci 2005; 17(1): 7-19.
[23]
Tang WK, Caeiro L, Lau CG, et al. Apathy and suicide-related ideation 3 months after stroke: A cross-sectional study. BMC Neurology 2015; 15: 60.
[24]
Onoda K, Yamaguchi S. Dissociative contributions of the anterior cingulate cortex to apathy and depression: Topological evidence from resting-state functional MRI. Neuropsychologia 2015; 77: 10-8.
[25]
Robert PH, Clairet S, Benoit M, et al. The apathy inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mils cognitive impairment. Int J Geriatr Psychiatry 2002; 17: 1099-105.
[26]
Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991; 38: 143-62.
[27]
Starkstein SE, Mayberg HS, Preziosi TJ, Andrerzejewswki P, Leiguarda R, Robinson RG. Reliability, validity and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992; 4: 134-9.
[28]
Weiser M, Garibaldi G. Quantifying motivational deficits and apathy: A review of the literature. Eur Neuropsychopharmacol 2015; 25: 1060-81.
[29]
Lane-Brown AT, Tate RL. Measuring apathy after traumatic brain injury: Psychometric properties of the Apathy Evaluation Scale and the Frontal Systems Behavior Scale. Brain Inj 2009; 23(13-14): 999-1007.
[30]
Arnould A, Rochat L, Azouvi P, Van der Linden M. Apathetic symptom presentations in patients with severe traumatic brain injury: Assessment, heterogeneity and relationships with psychosocial functioning and caregivers’ burden. Brain Inj 2015; 29(13-14): 1597-603.
[31]
Arnould A, Rochat L, Azouvi P, Van der Linden M. A multidimensional approach to apathy after traumatic brain injury. Neuropsychol Rev 2013; 23: 210-33.
[32]
Bortolon C, Macgregor A, Capdevielle D, Raffard S. Apathy in schizophrenia: A review of neuropsychological and neuroanatomical studies Neuropsychologia 2018; 118(B): 22-33.
[33]
Brodaty H, Sachdev PS, Withall A, Altendorf A, Valenzuela MJ, Lorentz L. Frequency and clinical, neuropsychological and neuroimaging correlates of apathy following stroke - the Sydney Stroke Study. Psychol Med 2005; 35: 1707-16.
[34]
Caeiro L, Ferro JM, Figueira ML. Apathy in acute stroke patients. Eur J Neurol 2012; 19: 291-7.
[35]
Cipriani G, Lucetti C, Danti S, Nuti A. Apathy and dementia. Nosology, assessment and management. J Nerv Ment Dis 2014; 202(10): 718-24.
[36]
Jorge RE, Starkstein SE, Robinson RG. Apathy following stroke. Can J Psychiatry 2010; 55(6): 350-4.
[37]
Rao V, McCann U, Bergey A, Han D. Correlates of apathy during the first year after traumatic brain injury. Psychosomatics 2013; 54(4): 403-4.
[38]
Robert G, Le Jeune F, Lozachmeur C, et al. Apathy in patients with Parkinson’s disease without dementia or depression. A PET study. Neurology 2012; 79: 1155-60.
[39]
Tang WK, Chen YK, Liang HJ, et al. Location of infarcts and apathy in ischemic stroke. Cerebrovasc Dis 2013; 35: 566-71.
[40]
Van Dalen JW, Van Charante EPM, Nederkoorn PJ, Van Gool WA, Richard E. Poststroke apathy. Stroke 2013; 44: 851-60.
[41]
Starkstein SE, Fedoroff P, Price TR, Leiguarda R, Robinson RG. Apathy following cerebrovascular lesions. Stroke 1993; 24: 1625-30.
[42]
Yang S-R, Hua P, Shang X-Y, Hu R, Mo X-E, Pan X-P. Predictors of early post-ischemic stroke apathy and depression: A cross-sectional study. BMC Psychiatry 2013; 13: 164.
[43]
Caeiro L, Santos O, Ferro JM, Figueira ML. Neuropsychiatric disturbances in acute subarachnoid haemorrhage. Eur J Neurol 2011; 18: 857-64.
[44]
Caeiro L, Ferro JM, Costa J. Apathy secondary to stroke: A systematic review and meta-analysis. Cerebrovasc Dis 2013; 35: 23-39.
[45]
Mayo NE, Fellows LK, Scott SC, Cameron J, Wood-Dauphinee S. A longitudinal view of apathy and its impact after stroke. Stroke 2009; 40: 3299-307.
[46]
Starkstein SE, Petracca G, Chemerinski E, Kremer J. Syndromic validity of apathy in Alzheimer’s disease. Am J Psychiatry 2001; 158(6): 872-7.
[47]
Kuhlmei A, Walther B, Becker T, Müller U, Nikolaus T. Actigraphic daytime activity is reduced in patients with cognitive impairment and apathy. J Eur Psychiatr 2013; 28: 94-7.
[48]
Benito-León J, Cubo E, Coronell C. on behalf of the ANIMO Study Group. Impact of apathy on health-related quality of life in recently diagnosed Parkinson’s disease: The ANIMO study. Mov Disord 2012; 27(2): 211-8.
[49]
Tang WK, Lau CG, Mok V, Ungvari GS, Wong KS. Apathy and health-related quality of life in stroke. Arch Phys Med Rehabil 2014; 95: 857-61.
[50]
Njomboro P, Humphreys GW, Deb S. Exploring social cognition in patients with apathy following acquired brain damage. BMC Neurology 2014; 14: 18.
[51]
Berridge KC, Kringlebach ML. Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology 2008; 199: 457-80.
[52]
Chau DT, Roth RM, Green AI. The neural circuitry of reward and its relevance to psychiatric disorders. Curr Psychiatr Rep 2004; 6: 391-9.
[53]
Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1994; 50: 873-80.
[54]
Alexander GE, DeLong MR, Strick PR. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-81.
[55]
Alexander GE, Crutcher MD. Functional architecture of the basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990; 13: 266-71.
[56]
Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamo-cortical circuits: Parallel substrates for motor, oculomotor, “prefrontal” and “limbic” function. Prog Brain Res 1991; 85: 119-46.
[57]
Haber SN, Fudge JL, McFarland NR. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci 2000; 20(6): 2369-82.
[58]
Hong S, Hikosaka O. The globus pallidus sends reward-related signals to the lateral habenula. Neuron 2008; 60: 720-9.
[59]
Devinsky O, Morrell MJ, Vogt BA. Contributions of anterior cingulate cortex to behaviour. Brain 1995; 118: 279-306.
[60]
Nachev P, Kennard C, Husain M. Functional role of the supplementary and pre-supplementary motor areas. Nat Rev Neurosci 2008; 9: 856-69.
[61]
Bella R, Pennisi G, Cantone M, et al. Clinical presentation and outcome of geriatric depression in subcortical ischemic vascular disease. Gerontology 2010; 56(3): 298-302.
[62]
Concerto C, Lanza G, Cantone M, et al. Different patterns of cortical excitability in major depression and vascular depression: A transcranial magnetic stimulation study. BMC Psychiatry 2013; 13: 300.
[63]
Pennisi M, Lanza G, Cantone M, et al. Correlation between motor cortex excitability changes and cognitive impairment in vascular depression: Pathophysiological insights from a longitudinal TMS study. Neural Plast 2016; 2016Article ID: 8154969
[64]
Guerra A, Petrichella S, Vollero L, et al. Neurophysiological features of motor cortex excitability and plasticity in subcortical ischemic vascular dementia: A TMS mapping study. Clin Neurophysiol 2015; 126: 906-13.
[65]
Konstantakopoulos G, Ploumpidis D, Oulis P, et al. Apathy, cognitive deficits and functional impairment in schizophrenia. Schizophr Res 2011; 133: 193-8.
[66]
Grool AM, Geerlings MI, Sigurdsoon S, et al. Structural MRI correlates of apathy symptoms in older persons without dementia. The AGES-Reykjavik study. Neurology 2014; 82: 1628-35.
[67]
Mitchell RA, Herrmann N, Lanctôt KL. The role of dopamine in symptoms and treatment of apathy in Alzheimer’s disease. CNS Neurosci Ther 2011; 17: 411-27.
[68]
Stanton BR, Leigh PN, Howard RJ, Barker GJ, Brown RG. Behavioural and emotional symptoms of apathy are associated with distinct patterns of bran atrophy in neurodegenerative disorders. J Neurol 2013; 260: 2481-90.
[69]
Yuen GS, Gunning FM, Woods E, Klimstra SA, Hoptman MJ, Alexopoulos GS. Neuroanatomical correlates of apathy in late-life depression and antidepressant treatment response. J Affect Disord 2014; 166: 179-86.
[70]
Holroyd CB, Yeung N. Motivation of extended behaviors by anterior cingulate cortex. Trends Cogn Sci 2012; 16(2): 122-8.
[71]
Bartra O, McGuire JT, Kable JW. The valuation system: A coordinate-based meta-analysis of BOLD fMRI experiments examining neural correlates of subjective value. Neuroimage 2013; 76: 412-27.
[72]
Bonnelle V, Veromann K-R, Burnett Heyes S, Lo Sterzo E, Manohar S, Husain M. Characterization of reward and effort mechanisms in apathy. J Physiol Paris 2015; 109: 16-26.
[73]
Bonnelle V, Manohar S, Behrens T, Husain M. Individual differences in premotor brain systems underlie behavioural apathy. Cereb Cortex 2106(26): 807-19.
[74]
Holroyd CB, Umemoto A. The research domain criteria framework: The case for anterior cingulate cortex. Neurosci Biobehav Rev 2016; 71: 418-33.
[75]
Rowe JB, Hughes L, Nimmo-Smith I. Action selection: A race model for selected and non-selected actions distinguishes the contribution of premotor and prefrontal areas. Neuroimage 2010; 51: 888-96.
[76]
Bromberg-Martin ES, Matsumoto M, Hikosaka O. Dopamine in motivational control: Rewarding, aversive and alerting. Neuron 2010; 68: 815-34.
[77]
Collins AGE, Frank MJ. Surprise! Dopamine signals mix action, value and error. Nat Neurosci 2016; 19: 3-5.
[78]
Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci 2004; 51: 1-12.
[79]
Berridge KC. The debate over dopamine’s role in reward: the case for incentive salience. Psychopharmacology 2007; 191: 391-431.
[80]
Syed ECJ, Grima LL, Magill PJ, Bogacz R, Brown P, Walton ME. Action initiation shapes mesolimbic dopamine encoding of future rewards. Nat Neurosci 2016; 19(1): 34-6.
[81]
Ivanov I, Liu X, Clerkin S, et al. Effects of motivation on reward and attentional networks: an fMRI study. Brain Behav 2012; 2(6): 741-53.
[82]
Westbrook A, Braver TS. Dopamine does double duty in motivating cognitive effort. Neuron 2016; 89: 695-710.
[83]
Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron 2012; 76: 470-85.
[84]
Hamid AA, Pettibone JR, Mabrouk OS, et al. Mesolimbic dopamine signals the value of work. Nat Neurosci 2016; 19(1): 117-26.
[85]
Chung SJ, Lee JJ, Ham JH, Lee PH, Sohn YH. Apathy and striatal dopamine defects in non-demented patients with Parkinson’s disease. Park Rel Dis 2016; 23: 62-5.
[86]
Dan R, Ruzicka F, Bezdicek O, et al. Separate neural representations of depression and apathy in Parkinson’s disease. Sci Rep 2017; 7: 12164.
[87]
Maillet A, Krack P, Lhommée E, et al. The prominent role of serotoninergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain 2016; 139: 2486-502.
[88]
Remy P, Doder M, Lees A, Turjansky N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128: 1314-22.
[89]
Adam R, Leff A, Sinha N, et al. Dopamine reverses reward insensitivity in apathy following globus pallidus lesions. Cortex 2013; 49: 1292-303.
[90]
Chong T-JT, Bonnelle V, Manohar S, et al. Dopamine enhances willingness to exert effort for reward in Parkinson’s disease. Cortex 2015; 69: 40-6.
[91]
Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, and Parkinson’s disease: influence of dopatherapy. Neuropsychologia 2002; 40: 2257-67.
[92]
Muhammed K, Manohar S, Ben Yehuda M, et al. Reward sensitivity deficits modulated by dopamine are associated with apathy in Parkinson’s disease. Brain 2016; 139: 2706-21.
[93]
Rochat L, Van der Linden M, Renaud O, et al. Poor reward sensitivity and apathy after stroke. Neurology 2013; 81: 1674-80.
[94]
Roth RM, Flashman LA, McAllister TW. Apathy and its treatment. Curr Treat Options Neurol 2007; 9: 363-70.
[95]
Berman K, Brodaty H, Withall A, Seeher K. Pharmacologic treatment of apathy in dementia. Am J Geriatr Psychiatry 2012; 20(2): 104-22.
[96]
Antonini A, Bauer L, Dohin E, et al. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol 2015; 22: 1400-7.
[97]
Hauser RA, Slawek J, Barone P, et al. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease. BMC Neurology 2016; 16: 90.
[98]
Smith KM, Eyal E, Weintraub D. For the ADAGIO group. Combined rasagiline and anti-depressant use in Parkinson’s disease in the ADAGIO study. Effects on non-motor symptoms and tolerability. JAMA Neurol 2015; 72(1): 88-95.
[99]
Pérez-Pérez J, Pagonabarraga J, Martínez-Horta S, et al. Head-to-head comparison of the neuropsychiatric effect of dopamine agonists in Parkinson’s disease: A prospective, cross-sectional study in non-demented patients. Drugs Aging 2015; 32: 401-7.
[100]
Devos D, Moreau C, Maltête D, et al. Rivastigmine in apathetic but dementia and depressin free patients with Parkinson’s disease: A double-blind, placebo controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2014; 85: 668-74.
[101]
Kohno N, Abe S, Toyoda G, Oguro H, Bokura H, Yamaguchi S. Successful treatment of post-stroke apathy by the dopamine receptor agonist ropinirole. J Clin Neurosci 2010; 17: 804-6.
[102]
Kohno N, Nabika Y, Toyoda G, Bokura H, Nagata T, Yamaguchi S. The effect of ropinirole on apathy and depression after herpes encephalitis. Cogn Behav Neurol 2012; 25(2): 98-102.
[103]
Monga V, Padala PR. Aripiprazole for treatment of apathy. Innov Clin Neur 2015; 12(9-10): 33-6.
[104]
Mikami K, Jorge RE, Moser DJ, et al. Prevention of post-stroke apathy using escitalopram or problem-solving therapy. Am J Geriatr Psychiatry 2013; 21(9): 855-62.
[105]
Blundo C, Gerace C. Dopamine agonists can improve pure apathy associated with lesions of the prefrontal-basal ganglia functional system. Ital J Neurol Sci 2015; 36: 1197-201.
[106]
Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson’s disease: Clinical features, neural substrates, diagnosis and treatment. Lancet Neurol 2015; 14: 518-31.
[107]
Robert P, Mulin E, Malléa P, David R. Apathy diagnosis, assessment and treatment in Alzheimer’s disease. CNS Neurosci Ther 2010; 16: 263-71.
Download PDF Flyer